Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Rises By 323.2%

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 187,900 shares, an increase of 323.2% from the February 28th total of 44,400 shares. Approximately 7.5% of the company’s shares are sold short. Based on an average daily trading volume, of 830,400 shares, the short-interest ratio is currently 0.2 days.

ZyVersa Therapeutics Stock Down 5.4 %

Shares of NASDAQ:ZVSA opened at $0.70 on Friday. ZyVersa Therapeutics has a 12 month low of $0.65 and a 12 month high of $8.40. The company has a 50-day moving average price of $1.12 and a 200-day moving average price of $1.47.

Institutional Trading of ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new stake in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 3.91% of the company’s stock.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.